| Autor: |
Harrysson, Sara, Eloranta, Sandra, Ekberg, Sara, Enblad, Gunilla, Andersson, Per-Ola, Sonnevi, Kristina, Ljungqvist, Maria, Sander, Birgitta, Jerkeman, Mats, Smedby, Karin E. |
| Předmět: |
|
| Zdroj: |
Leukemia & Lymphoma; Apr2024, Vol. 65 Issue 4, p534-537, 4p |
| Abstrakt: |
This document discusses the outcomes for patients with secondary central nervous system (CNS) involvement in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and estimates their eligibility for CAR T-cell therapy. Secondary CNS lymphoma (SCNSL) is associated with poor survival, and there is currently no established standard therapy for this condition. The document presents a study that investigated the outcomes of 145 consecutive SCNSL patients treated in clinical routine and estimated the proportion and outcome of those who could potentially have been eligible for CAR T-cell therapy. The study found that only a small percentage of patients met the eligibility criteria for CAR T-cell therapy. The study suggests that alternative treatment options are needed for these high-risk patients, including CAR T-cell therapy. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
